Date: 14 Aug 2014

HIV and Stem Cell Transplantation

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


In human immunodeficiency virus (HIV)-infected persons, the incidence of hematologic malignancies, including leukemia and lymphoma, is increased despite the use of successful antiretroviral therapy. Hematopoietic stem cell transplantation (SCT) is emerging as a safe and effective therapy for HIV-infected persons with hematologic malignancies. Management of these patients is complicated by drug–drug interactions involving antiretroviral therapy (ART) that may impact conditioning agent efficacy and metabolism of immunosuppressive medications and potentiate drug toxicities. As such, optimal strategies for ART remain controversial. We discuss recent advances, controversies, and future directions related to SCT in HIV-infected persons, including the investigation of allogeneic SCT as a strategy for HIV cure.

This article is part of the Topical Collection on Transplant and Oncology
Ignacio A. Echenique and George E. Nelson these authors contributed equally to the work